These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867 [TBL] [Abstract][Full Text] [Related]
4. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593 [TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study. Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders. Gane EJ; Rouzier R; Wiercinska-Drapalo A; Larrey DG; Morcos PN; Brennan BJ; Le Pogam S; Nájera I; Petric R; Tran JQ; Kulkarni R; Zhang Y; Smith P; Yetzer ES; Shulman NS Antimicrob Agents Chemother; 2014; 58(2):1136-45. PubMed ID: 24295986 [TBL] [Abstract][Full Text] [Related]
7. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Izumi N; Yokosuka O; Kawada N; Osaki Y; Yamamoto K; Sata M; Ishikawa H; Ueki T; Hu W; McPhee F; Hughes EA; Kumada H Antivir Ther; 2014; 19(5):501-10. PubMed ID: 24451151 [TBL] [Abstract][Full Text] [Related]
8. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT; N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351 [TBL] [Abstract][Full Text] [Related]
9. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Rustgi VK; Esposito S; Hamzeh FM; Shiffman ML Aliment Pharmacol Ther; 2008 Mar; 27(5):433-40. PubMed ID: 18081737 [TBL] [Abstract][Full Text] [Related]
10. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553 [TBL] [Abstract][Full Text] [Related]
11. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Rodriguez-Torres M; Lawitz E; Yangco B; Jeffers L; Han SH; Thuluvath PJ; Rustgi V; Harrison S; Ghalib R; Vierling JM; Luketic V; Zamor PJ; Ravendhran N; Morgan TR; Pearlman B; O'Brien C; Khallafi H; Pyrsopoulos N; Kong G; McPhee F; Yin PD; Hughes E; Treitel M Ann Hepatol; 2016 Nov-Dec 2016; 15(6):834-845. PubMed ID: 27740516 [TBL] [Abstract][Full Text] [Related]
12. Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort. Ascione A; Bruno S; Coppola C; Mangia A; Orlandini A; Schmitz M; Deodato B; Puoti M Hepatogastroenterology; 2014 Jun; 61(132):1094-106. PubMed ID: 26158171 [TBL] [Abstract][Full Text] [Related]
13. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C; N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352 [TBL] [Abstract][Full Text] [Related]
14. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S; N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903 [TBL] [Abstract][Full Text] [Related]
15. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Pockros PJ; Nelson D; Godofsky E; Rodriguez-Torres M; Everson GT; Fried MW; Ghalib R; Harrison S; Nyberg L; Shiffman ML; Najera I; Chan A; Hill G Hepatology; 2008 Aug; 48(2):385-97. PubMed ID: 18570306 [TBL] [Abstract][Full Text] [Related]
16. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies. Kumada H; Mochida S; Suzuki F; Chayama K; Karino Y; Nakamura K; Fujimoto G; Howe AY; Ludmerer SW; Mobashery N J Gastroenterol Hepatol; 2016 Oct; 31(10):1674-1683. PubMed ID: 26936417 [TBL] [Abstract][Full Text] [Related]
17. Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. Asselah T; Esmat G; Sanai FM; Goulis I; Messinger D; Bakalos G; Waked I Adv Ther; 2016 Oct; 33(10):1797-1813. PubMed ID: 27517563 [TBL] [Abstract][Full Text] [Related]
18. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. Kao JH; Tung SY; Lee Y; Thongsawat S; Tanwandee T; Sheen IS; Wu JJ; Li H; Brennan BJ; Zhou J; Le Pogam S; Najera I; Thommes JA; Hill G J Gastroenterol Hepatol; 2016 Oct; 31(10):1757-1765. PubMed ID: 26992248 [TBL] [Abstract][Full Text] [Related]
19. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection. Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122 [TBL] [Abstract][Full Text] [Related]
20. Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. Liu CH; Huang CF; Liu CJ; Dai CY; Huang JF; Lin JW; Liang CC; Yang SS; Lin CL; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Kao JH; Yu ML Sci Rep; 2015 Oct; 5():15255. PubMed ID: 26469083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]